» Articles » PMID: 30544059

Changes in FIT Values Below the Threshold of Positivity and Short-term Risk of Advanced Colorectal Neoplasia: Results from a Population-based Cancer Screening Program

Abstract

Introduction: Increased values in the fecal immunochemical test (FIT) are correlated with increasingly severe colorectal neoplasia, but little attention has been given to FIT values below the cut-off point (negative FIT, nFIT). We analysed the relationship between the concentrations of two consecutive nFIT and the risk of following screen-detected advanced neoplasia and interval cancer (IC) in a population-based colorectal cancer screening program.

Methods: FIT results were categorised into non-detectable nFIT (0-3.8 μg haemoglobin/g feces), low nFIT (3.9-9.9) and high nFIT (10.0-19.9). Multivariable adjusted logistic regression was used to estimate the odds ratios (OR) of advanced neoplasia and IC with the nFIT results in the first two screens.

Results: More than 90% of the 42,524 persons had non-detectable nFIT in the first and second screen; 4.5% and 5.8% had a low nFIT, respectively, and 2.2% and 2.9% had a high nFIT. The probability of testing positive and being diagnosed of advanced neoplasia or IC rose with increasing values of nFIT. Compared with those with two non-detectable nFIT results, the highest OR were found among those who had two high nFIT results (OR 21.75; 95% confidence interval: 12.44, 38.04) and those with one low nFIT and one high nFIT (ORs around 20).

Conclusions: Participants with nFIT results above the detection limit of the test had an increased risk of advanced neoplasia and IC in subsequent participations. This information could be used in the design of personalised screening strategies.

Citing Articles

Changes in faecal haemoglobin values over sequential rounds of faecal immunochemical tests (FIT) in a surveillance population.

Mortell G, Wooldrage K, Murphy G, Cross A BMJ Open Gastroenterol. 2025; 12(1).

PMID: 39933781 PMC: 11843008. DOI: 10.1136/bmjgast-2024-001651.


Interval cancer risk after the upper age limit of screening has been reached: Informing risk stratification in FIT-based colorectal cancer screening.

van Stigt B, Lansdorp-Vogelaar I, Spaander M, van Vuuren A, Dekker E, van Kemenade F Int J Cancer. 2024; 156(9):1783-1790.

PMID: 39697047 PMC: 11887016. DOI: 10.1002/ijc.35294.


An Adjustable Positivity Threshold for Non-invasive Screening Tests for Colorectal Neoplasms Can Improve Screening Program Effectiveness and Feasibility.

Young G, Senore C, Schoengold R, Laven-Law G, Saito H, Symonds E Dig Dis Sci. 2024; .

PMID: 39384709 DOI: 10.1007/s10620-024-08657-6.


A single measurement of fecal hemoglobin concentration outperforms polygenic risk score in colorectal cancer risk assessment.

Niedermaier T, Alwers E, Chen X, Heisser T, Hoffmeister M, Brenner H Cancer Commun (Lond). 2023; 43(8):947-950.

PMID: 37272255 PMC: 10397559. DOI: 10.1002/cac2.12448.


Personalized colorectal cancer screening: study protocol of a mixed-methods study on the effectiveness of tailored intervals based on prior f-Hb concentration in a fit-based colorectal cancer screening program (PERFECT-FIT).

Breekveldt E, Toes-Zoutendijk E, de Jonge L, Spaander M, Dekker E, van Kemenade F BMC Gastroenterol. 2023; 23(1):45.

PMID: 36814185 PMC: 9948315. DOI: 10.1186/s12876-023-02670-1.